Nucleai Overview
Nucleai’s technology leverages intelligence-grade geospatial AI methods to analyze and interpret complex cellular interactions in a patient’s biopsy, translating them into actionable insights that can accelerate the development of life-saving treatments and diagnostics. The company deploys an AI spatial tool for patient selection in a clinical trial, in partnership with a top 10 biopharma company. The platform pioneers AI-driven spatial biomarker analysis, offering a first-of-its-kind multimodal solution. It ingests images from various modalities (H&E, IHC, and multiplex immunofluorescence), conducts advanced spatial analysis, and delivers actionable insights. These insights empower pathologists and researchers with an AI-powered data-rich action plan, paving the way for more informed decisions in the development of next-generation treatments such as bi-specifics, antibody-drug conjugates (ADCs), and immunotherapy. Nucleai is working with more than 60 percent of the Top 20 biopharma companies in the world, and has an ecosystem of partners across diagnostics, contract research organizations (CROs), and life sciences tools companies.
Cumulative Funding Raised Over Time ($)
$14.0MApr 2024
$22.5MJul 2020
$27.5MMar 2018
$60.5MMar 2022
Latest News
הסטארטאפ Nucleai מפטר 15% מהעובדים
growth-positive
Proscia and Nucleai Partner to Integrate Predictive Biomarker Solutions
Proscia, a provider of AI-powered pathology solutions, and Nucleai, a spatial AI biomarker company, have announced a strategic partnership. The collaboration aims to integrate Nucleai’s biomarker technology with Proscia’s Concentriq software platform to improve the efficiency and effectiveness of developing new treatments and delivering patient care. Nucleais AI technology analyzes whole slide images, generating spatial maps that predict therapeutic outcomes. Proscia’s Concentriq platform serves as a central hub for all digital pathology data and AI-enabled workflows across the entire diagnostic process.
Partners
Nucleai and GoPath Diagnostics Announce Strategic Collaboration to Provide Integrated AI-powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications
growth-positive
Spatial AI biomarker startup Nucleai raises $14 million led by Merck's VC arm | CTech
Nucleai, an AI biomarker company, has secured a $14 million investment led by M Ventures, the corporate venture capital arm of Merck KGaA. The funding will be used to further deploy its AI algorithms for the prospective enrollment of patients in clinical trials. Nucleais technology provides pathologists with the intelligence to anticipate and navigate complex diseases, like cancer. The company has collaborations with over 60% of the top 20 biopharma companies. The funding will also support Nucleais work in the rapidly emerging areas of immunotherapies, antibody-drug conjugates, and bi-specifics.
Investment
Lunaphore and Nucleai announce a partnership to provide AI-powered spatial biology analysis to accelerate drug development
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $60.5M |
| Last funding | $14M |
| Stage | B |
| Rounds | 4 |
| Investors | 11 |
Team Members
6
Employees: 51-200
Web & Social Links
| Website | nucleai.ai/ |
| Careers | Careers page |
Locations
Ein Zeitim St 4, Tel Aviv-Yafo, Israel
1375 W Fulton St, Chicago, IL 60607, USA
Photos & Videos
1 item(s)
Nucleai Business
Business models
B2B
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesDigital HealthcareMedical Decision SupportTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcareProvidersLaboratoriesCore Technology
Artificial IntelligenceMachine LearningComputer VisionData StorageCloudPlatforms & InterfacesSoftwareTags (24)
bioconvergencecancer-diagnosticshealthcare-providersmachine-learningdiagnosticsoncologycancerdigital-healthcaredeep-learningartificial-intelligencecomputer-visionprecision-medicinemedical-technologieshospitalsimagingbiomarkerssoftware-platformcloud-basedlaboratoriesdecision-supportpharmaceuticalspharma-companiesimmunotherapyclinical-trialsGeographic Markets
EuropeUnited StatesNucleai Financials
$60.5M
Total funding
Undisclosed
Capital raised
$14M
Last funding
B
Funding stage
4
Total rounds
11
Investors
Cumulative Funding Raised Over Time ($)
$14.0MApr 2024
$22.5MJul 2020
$27.5MMar 2018
$60.5MMar 2022
Private Equity Funding
B Round
Apr 2024
$14M
M Ventures (Lead)
,
Debiopharm Innovation Fund, Vertex Ventures Israel, Sanofi Ventures, Grove Ventures, Section 32, Fosun RZ Capital
B Round
Mar 2022
$33M
Sanofi Ventures, Vertex Ventures Israel, Fosun RZ Capital, Undisclosed Investor(s), Grove Ventures, Section 32, Debiopharm Group
A Round
Jul 2020
$8.5M
Debiopharm Group (Lead)
,
Grove Ventures, Vertex Ventures Israel
Seed
Mar 2018
$5M
Grove Ventures, Nir Kalkstein, Vertex Ventures Israel, Brian Cooper
Nucleai Lifecycle
Cumulative Funding Raised Over Time
$14.0MApr 2024
$22.5MJul 2020
$27.5MMar 2018
$60.5MMar 2022
All Events
B Round
Apr 2024
$14M
M Ventures (Lead)
,
Debiopharm Innovation Fund, Vertex Ventures Israel, Sanofi Ventures, Grove Ventures, Section 32, Fosun RZ Capital
B Round
Mar 2022
$33M
Sanofi Ventures, Vertex Ventures Israel, Fosun RZ Capital, Undisclosed Investor(s), Grove Ventures, Section 32, Debiopharm Group
A Round
Jul 2020
$8.5M
Debiopharm Group (Lead)
,
Grove Ventures, Vertex Ventures Israel
Seed
Mar 2018
$5M
Grove Ventures, Nir Kalkstein, Vertex Ventures Israel, Brian Cooper
Nucleai News
25 articlesהסטארטאפ Nucleai מפטר 15% מהעובדים
growth-positive
Proscia and Nucleai Partner to Integrate Predictive Biomarker Solutions
Proscia, a provider of AI-powered pathology solutions, and Nucleai, a spatial AI biomarker company, have announced a strategic partnership. The collaboration aims to integrate Nucleai’s biomarker technology with Proscia’s Concentriq software platform to improve the efficiency and effectiveness of developing new treatments and delivering patient care. Nucleais AI technology analyzes whole slide images, generating spatial maps that predict therapeutic outcomes. Proscia’s Concentriq platform serves as a central hub for all digital pathology data and AI-enabled workflows across the entire diagnostic process.
Partners
Nucleai and GoPath Diagnostics Announce Strategic Collaboration to Provide Integrated AI-powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications
growth-positive
Spatial AI biomarker startup Nucleai raises $14 million led by Merck's VC arm | CTech
Nucleai, an AI biomarker company, has secured a $14 million investment led by M Ventures, the corporate venture capital arm of Merck KGaA. The funding will be used to further deploy its AI algorithms for the prospective enrollment of patients in clinical trials. Nucleais technology provides pathologists with the intelligence to anticipate and navigate complex diseases, like cancer. The company has collaborations with over 60% of the top 20 biopharma companies. The funding will also support Nucleais work in the rapidly emerging areas of immunotherapies, antibody-drug conjugates, and bi-specifics.
Investment
Lunaphore and Nucleai announce a partnership to provide AI-powered spatial biology analysis to accelerate drug development
Nucleai Announces New Data Showing Better Prediction of Response to Immune Checkpoint Inhibitors for NSCLC Patients
Nucleai Appoints New Head of Pathology to Support Expansion in Biopharmaceutical and Clinical Markets
growth-positive
Nucleai Announces a Partnership with Sirona Dx for AI-Driven Discovery of Novel Spatial Biomarkers in Solid Tumors
Israeli startup Nucleai has partnered with US-based contract research organization Sirona DX to further the AI-driven discovery of novel spatial biomarkers in solid tumors. Nucleais precision oncology platform combines AI spatial analytics with Sirona Dxs expertise to uncover spatial signatures that predict response to therapy. The partnership aims to support biopharma clinical trials and improve patient care. Nucleai previously raised $33 million in a Series B funding round to expand its spatial biology platform.
Partners
Nucleai Announces Partnership with Ultivue to Provide AI-Powered Spatial Biology Analysis to Complex Pathology Images
growth-positive
Nucleai raises $33 million for spatial biology drug development platform CTech
Israeli startup Nucleai has raised $33 million in Series B funding led by Section 32 and Sanofi Ventures. The company has developed technology that allows better prediction of a patients response to specific oncological treatment, improving the chances of developing new cancer drugs. The funding brings Nucleais total investment to $50 million. Nucleais platform is being adopted by pharmaceutical companies worldwide to analyze the rich information available in biopsies and produce scientific discoveries that can change the treatment of cancer.
Investment
growth-positive
The Israeli startup using spatial biology to provide better cancer treatment
Israeli startup Nucleai combines artificial intelligence, big data, and computational biology to develop precision medicine solutions for cancer treatment. The companys software uses computer vision and machine learning algorithms to predict the progress of cancerous tumors and individual patients immune system responses. Nucleai is working with pharmaceutical companies to develop better drugs and recommends cancer patients enroll in clinical trials. The company has raised $15 million in funding from investors including Debiopharm, Vertex Ventures, Grove Ventures, and Fusun RZ Capital. Nucleai plans to expand its operations and open branches in Boston and the Bay Area.
PartnersInvestmentExpand
Nucleai and Merck KGaA Darmstadt, Germany Launch Translational Medicine Collaboration Utilizing Nucleai's AI-Powered Biomarker Platform
growth-positive
https://www.jpost.com/health-science/israeli-ai-firm-nucleai-sheba-launch-partnership-for-data-collaboration-661267
Israeli AI firm Nucleai is partnering with Sheba Medical Centers ARC Innovation Center for a strategic data collaboration. Nucleai will gain access to millions of patient records at Sheba Medical Center, including pathology images, clinical data, genomics, and radiomics. The partnership aims to advance the study of technological and AI-based solutions in the discovery of histological biomarkers. Nucleai and Sheba have previously collaborated on identifying biomarkers for non-small-cell lung cancer patients. They have successfully demonstrated the prediction efficiency of tumor microenvironment AI-based analysis for breast cancer. Nucleai plans to leverage Shebas data repository to enhance their AI and machine learning algorithms and develop robust digital pathology platforms.
Partners
growth-positive
Nucleai and Debiopharm Launch Research Collaboration Utilizing Nucleai's AI-Powered Biomarker Platform - Debiopharm
Nucleai and Debiopharm have entered into a long-term collaboration to leverage Nucleais AI-powered biomarker research & discovery platform for one of Debiopharms clinical stage oncology assets. Nucleais platform analyzes tissue images using computer vision and machine learning to create unique histological biomarkers that can predict patient response. This collaboration could result in better patient selection and improved clinical performance for Debiopharms therapeutic development programs in oncology. The agreement includes an initial installment to Nucleai followed by success-based milestone payments.
Partners
growth-positive
How AI Helps Advance Immunotherapy And Precision Medicine
Tel-Aviv-based startup Nucleai is developing AI software for image analysis and modeling of pathology data to assist in the development of more effective drugs. The company aims to be a leader in precision medicine and uses a multi-disciplinary approach to address the challenge of ineffective predictive biomarkers. Nucleais novel approach to spatial biology helps identify predictive patterns for better selection of candidates in drug trials. The company has raised $13 million, including $8 million in a series A round led by Debiopharm Group. Other investors include Grove Ventures and Vertex Ventures Israel. Nucleai differentiates itself through big data analysis and its go-to-market approach. The article highlights the potential of AI in pathology and the need for a digital transformation in the field.
Investment
growth-positive
החברה שמנבאת הצלחת תרופות לסרטן על ידי פענוח הדמיות
Israeli company NucleAI, which uses artificial intelligence to interpret medical imaging for personalised cancer treatment, has raised $8.5m in a funding round led by Swiss pharmaceutical company Debiopharm. The company is working with drug companies and insurers on long-term contracts that are expected to generate millions of dollars in revenue. NucleAI, which employs 30 people, was founded in 2017 by Avi Veidman, Eliron Amir and Lotan Chorev.
Investment
growth-positive
AI cancer treatment startup Nucleai raises $6.5 million in series A round
Tel Aviv-based cancer detection startup Nucleai Ltd. has raised $6.5 million in a series A round led by Debiopharm Group. The funding will be used for research and development and expanding commercial reach. Nucleais software uses computer vision and machine learning to predict tumor progress and patient immune system response for efficient treatment. Nucleai and Debiopharm will collaborate on predictive biomarker discovery and improving clinical trial data. Nucleai was founded in 2017 and employs 30 people. The company plans to raise an additional $2-3 million to complete the funding round.
InvestmentPartners
growth-positive
Nucleai Partners with Protean BioDiagnostics to Improve Cancer Diagnosis
Nucleai, an AI company, has partnered with Protean BioDiagnostics to enhance cancer diagnostic technology. They will synchronize Nucleais AI-based services with Protean BioDiagnostic laboratories advanced diagnostic tools. The partnership aims to improve diagnostic evaluation and advance personalized oncology technology. Nucleai will benefit from Protean BioDiagnostics expertise in precision medicine, while Protean BioDiagnostics will gain access to Nucleais advanced AI technology. The collaboration holds promise for better diagnostics and reduced biopsy bottleneck.
Partners
growth-positive
This Israeli startup leverages AI to help pathologists handle their workload
Israeli startup Nucleai, founded in 2017, is using AI-based technology to assist pathologists in analyzing slides and creating accurate reports for GI, breast, and prostate biopsies. The companys tool can be utilized for quality assurance checks and as a digital resident that generates initial reports for pathologists to review. Nucleai has raised $5 million in funding and has customers in Israel, the U.S., and Europe. The company plans to expand its capabilities to more labs and organizations in the U.S. and Europe and is on the verge of signing strategic partnerships with various companies.
CustomersPartners
growth-positive
Nucleai Announces Participation in United States and Canadian Academy of Pathology (USCAP) Annual Meeting 2019
Nucleai, an AI company specializing in pathology, will be exhibiting at the 2019 United States and Canadian Academy of Pathology (USCAP) conference. The company offers AI-based analysis of biopsies to improve cancer diagnostics. Nucleais products analyze biopsies in the GI, breast, and prostate categories, providing increased efficiency and accuracy for pathologists. The company will be presenting its latest research on digital image analysis and artificial intelligence-based digital image analysis at the conference. Nucleai aims to improve the standard of care in oncology and has raised $5 million in funding to date.
PartnersCustomers
growth-positive
Precipio and Nucleai Partner to Develop Artificial Intelligence-Powered Hemepath Solution
Specialty diagnostics company Precipio has announced an agreement with Nucleai, an Israel-based artificial intelligence pathology platform company. Nucleais technology uses machine learning and machine vision algorithms to assist pathologists in the detection of cancer using biopsy image analysis. The partnership will focus on adapting the platform to the identification of abnormalities in hematopoietic malignancies. The use of Nucleais technology is expected to reduce scanning time, improve accuracy, and increase the throughput of cases. The collaboration aims to provide a more accurate diagnosis and potentially save resources and lives in cancer care. Precipios expertise and partnerships with academic-level medical school pathology departments will contribute to the development of the platform. The companies estimate that the time spent by hematopathologists on the morphologic assessment can be reduced by as much as 50%, resulting in potential cost savings and improved diagnostic outcomes.
PartnersExpand
growth-positive
Sequoia, Index, Andreessen And Samsung Just Backed These Israeli Startups
The article highlights several Israeli startups that have recently raised funding. The startups mentioned are AudioBurst, Nucleai, PixCell Medical, Capitolis, eToro, BioCatch, Luminate Security, and RapidAPI. The investments and funding rounds range from Samsung Venture Investment investing in AudioBurst to eToro raising $100M in a Round E. The article discusses startups in various sectors such as AI, digital health, fintech, cyber, and software. The funding and investments mentioned in the article indicate positive growth for the companies involved.
InvestmentExpand
Growth-Positive
Israeli AI Cancer Startup Lands $5 Million Tissuepathology.com
Israeli start-up Nucleai has raised $5m in a seed funding round led by Vertex Ventures Israel and Grove Ventures Capital. The company is developing an artificial intelligence (AI) pathology system to help pathologists detect signs of cancer and gastrointestinal diseases. The technology is designed to improve the efficiency of pathologists, reduce errors and shorten patients wait time for a diagnosis. The AI market for healthcare applications is expected to grow at 40% annually through 2021 and reach $6.7bn by that year, according to a report by Frost & Sullivan.
Investment
growth-positive
Israeli startup aims at disease diagnosis, helping pathologists process biopsies
Israeli startup Nucleai is developing an AI pathology system to help pathologists process and analyze biopsies more accurately and quickly. The company has raised $5 million in financing from Vertex Ventures, Grove Ventures, and private investors. Nucleais software uses computer vision, algorithms, and artificial intelligence to scan biopsies and identify problematic ones for pathologists. The technology will be deployed in hospitals and research centers in Israel and the US. The global AI market for healthcare applications is expected to reach $6.7 billion by 2021. Nucleai plans to double its team by recruiting experienced machine learning researchers.
CustomersInvestment
growth-positive
AI Cancer Detection Startup Nucleai Raises $5 Million
Tel Aviv-based Nucleai Ltd. has completed a $5 million Seed Round led by Vertex Ventures Israel and Grove Ventures Capital (GP) Ltd. The company develops software that uses artificial intelligence to diagnose abnormalities in tissue samples, particularly for detecting cancerous cells and gastrointestinal diseases. Nucleais technology aims to improve the efficiency of pathologists, reduce errors, and shorten patients wait time for a diagnosis. The company plans to launch a pilot in hospitals and labs in the U.S. and Israel in the coming months. Nucleai was founded in 2017 and is looking to double the size of its team.
InvestmentExpand
Nucleai Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 76 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 15 classification IDs that could be used for matching.
Nucleai Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Jenny Sotnik-Talisman |
| Registrar ID | 515742096 |
| Crunchbase | nucleai |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-06-04T00:00:00.000Z |
| Created | 2017-10-29T00:00:00.000Z |
| Claimed | Yes |